Tracer Development

此P50补助金申请的示踪剂开发专业资源（核心B）提供 在人类和动物中进行造影剂、质量控制和代谢物分析， 研究和试点项目。核心的活动将包括八项主要服务：1）生产 正电子发射放射性核素18F和11 C; 2）合成W-1-氨基-3-[18F]氟环丁基-1- 用于研究项目#1和核A、C和D的18F-[18F]FACBC; 3）合成18F标记的 CXCR 4拮抗剂和18F标记的CCR 7拮抗剂，用于研究项目#2和核心A、C， D. 4）合成细胞特异性的氨基末端断裂共轭氧化铁纳米粒子 研究项目#3和核心A、C的尿激酶纤溶酶原激活物（uPAR）表面受体，以及 D; 5）用于研究项目#4和核心A、C和D的MHI-148-AN缀合物的合成; 6）至 通过将99 mTc偶联到氨基末端肽上来合成肿瘤靶向的99 mTc-ATF肽 试验项目#1和核心A的尿激酶纤溶酶原激活物（uPA）受体片段（ATF）， 和D; 7）合成11 C-标记的PK 11195和11 C-标记的PK 11195拮抗剂1-（2-碘苯基）-N-甲基- 用于中试项目#4和核A、C和D的N-（3-[18F]氟丙基）-3-异喹啉甲酰胺;和8） 协助编写RDRC、IACUC、IND和IRB方案，以获得使用 研究项目#1、2、3和4，核心A、C和D以及试点的人体和动物放射性 项目#1，3和4。 在这方面，专门资源（核心B）构成部分是高度一体化的，由所有4个 研究项目和试点项目，并与彼此进行合作互动 丹

The Tracer Development Specialized Resource (Core B) of this P50 grant application provides the contrast agents, quality control and metabolite analysis in humans and animals to assist the individual research and pilot projects. The activities of the Core will consist of eight primary services: 1) to produce the positron emitting radionuclides 18F and 11C; 2) to synthesize anW-1-amino-3-[18F]fluorocyclobutyl-1- carboxylic acid (a/itf-[18F]FACBC) for Research Project #1 and Cores A, C and D; 3) to synthesize an 18Flabeled CXCR4 antagonist and an 18F-labeled CCR7 antagonist for Research Project #2 and Cores A, C, and D; 4) to synthesize amino terminal fragmented-conjugated iron oxide nanoparticles specific for the cell surface receptor of urokinase plasminogen activator (uPAR) for Research Project #3 and Cores A, C, and D; 5) The synthesis of MHI-148-AN conjugates for Research Project #4 and Cores A, C, and D; 6) to synthesize the tumor targeted 99mTc-ATF peptide by conjugating 99mTc to the amino-terminal peptide fragment (ATF) of the receptor for urokinase plasminogen activator (uPA) for Pilot Project #1 and Cores A, and D; 7) to synthesize 11C-labeled PK11195 and the %-labeled PK11195 antagonist, 1-(2-iodophenyl)-Nmethyl- N-(3-[18F]fluoropropyl)-3-isoquinolinecarboxamide for Pilot Project #4 and Cores A, C and D; and 8) to assist in the preparation of RDRC, IACUC, IND and IRB protocols for regulatory approval of the use of radioactivity in humans and animals for Research Projects #1, 2, 3, and 4, Cores A, C, and D, and Pilot Projects #1, 3, and 4. In this regard, the Specialized Resource (Core B) component is highly integrative, being utilized by all 4 Research Projects and of the Pilot Projects, and having collaborative interactions with each of the other cores.